Verdence Capital Advisors LLC Has $7.83 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Verdence Capital Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,190 shares of the company’s stock after purchasing an additional 1,891 shares during the period. Verdence Capital Advisors LLC’s holdings in Johnson & Johnson were worth $7,826,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Mayflower Financial Advisors LLC raised its position in shares of Johnson & Johnson by 1.1% during the first quarter. Mayflower Financial Advisors LLC now owns 15,277 shares of the company’s stock worth $2,533,000 after purchasing an additional 165 shares during the period. Hudock Inc. lifted its stake in Johnson & Johnson by 2.4% in the 1st quarter. Hudock Inc. now owns 13,706 shares of the company’s stock worth $2,273,000 after acquiring an additional 317 shares in the last quarter. Napatree Capital LLC lifted its stake in Johnson & Johnson by 10.1% in the 1st quarter. Napatree Capital LLC now owns 6,560 shares of the company’s stock worth $1,088,000 after acquiring an additional 604 shares in the last quarter. Lineweaver Wealth Advisors LLC lifted its stake in Johnson & Johnson by 6.4% in the 1st quarter. Lineweaver Wealth Advisors LLC now owns 21,235 shares of the company’s stock worth $3,521,000 after acquiring an additional 1,278 shares in the last quarter. Finally, Allen Capital Group LLC lifted its stake in Johnson & Johnson by 14.5% in the 1st quarter. Allen Capital Group LLC now owns 22,903 shares of the company’s stock worth $3,798,000 after acquiring an additional 2,893 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $164.78 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market cap of $396.47 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 2.12 and a beta of 0.41. The business’s 50-day simple moving average is $153.95 and its 200-day simple moving average is $154.71. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.82 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.16%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Morgan Stanley reissued an “underperform” rating on shares of Johnson & Johnson in a research note on Thursday, July 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Finally, Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.